DURHAM, N.C., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the recently adopted FY 2026 U.S. Department of Defense (DoD) Appropriations Act includes dedicated funding to support the evaluation and incorporation of biologic vascular repair technologies for the warfighters suffering from traumatic vascular injuries. The FY2026 National ...

Humacyte, Inc. (HUMA) closed the most recent trading day at $1.02, moving +2.24% from the previous trading session. The stock's change was more than the S&P 500's daily gain of 0.54%. At the same time, the Dow added 1.05%, and the tech-heavy Nasdaq gained 0.56%. Coming into today, shares of the company had gained 2.33% in the past month. In that same time, the Medical sector lost 1.89%, while the S&P 500 gained 0.74%. The investment community will be closely monitoring the performance of Humacyte, Inc. in i ...

Core Insights - Humacyte, Inc. announced results from a five-year analysis of hospital charges and healthcare costs related to extremity arterial injuries, highlighting the financial burden of preventable complications [1][2][5] Group 1: Financial Impact of Complications - Average hospital charge for extremity arterial injury repair was $316,600 per patient, with preventable complications like amputation and conduit infection increasing charges by approximately $493,000 and $590,000 respectively [1][3] - The average reimbursed cost for extremity arterial injury repair was significantly lower at $75,947, indicating a disparity between hospital charges and reimbursement [3] - Vascular graft infection and amputation resulted in additional hospital charges of $589,921 and $492,986 respectively, with average reimbursements of $84,598 and $116,611 [3] Group 2: Symvess Product Overview - Humacyte's Symvess is an acellular tissue engineered vessel designed for urgent revascularization in extremity arterial injuries when autologous vein grafts are not feasible [4][6] - Symvess has demonstrated low rates of infection and high limb salvage rates compared to historical controls, with infection rates one-ninth and amputation rates one-fifth of those seen with synthetic grafts [4][5] - The product is designed to be available off-the-shelf, which can save critical surgical time in emergency situations [5] Group 3: Clinical and Market Context - The analysis included data from 964 adult patients treated for extremity arterial injuries from 2018 to 2023, prior to the FDA approval of Symvess [2] - The patient cohort had an average age of 36.5 years, with 26% treated using conduits other than autologous vein, indicating a significant market for alternative solutions like Symvess [3][5] - Recent positive results from the V005 Phase 2/3 study of Symvess provide the first long-term data for traumatic arterial repair using a biologic conduit [5]

Group 1 - Humacyte, Inc. (HUMA) has gained approximately 12.4% year-to-date, outperforming the average gain of 7.6% for Medical stocks [4] - The Zacks Rank for Humacyte, Inc. is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The consensus estimate for Humacyte's full-year earnings has increased by 15.9% over the past quarter, reflecting improved analyst sentiment [3] Group 2 - Humacyte, Inc. is part of the Medical - Biomedical and Genetics industry, which has an average gain of 18.6% this year, indicating that HUMA is slightly underperforming its industry [5] - Acrivon Therapeutics, Inc. (ACRV), another Medical stock, has outperformed the sector with a return of 24.9% year-to-date [4] - The Medical - Drugs industry, to which Acrivon belongs, has gained 3.1% this year and is ranked 90 among 141 stocks [6]

Core Viewpoint - Humacyte, Inc. plans to file a Marketing Authorization Application (MAA) with the Israel Ministry of Health for its acellular tissue engineered vessel (ATEV™ or Symvess) aimed at arterial trauma repair, with expectations for expedited commercialization in other regions following FDA approval [1][2]. Group 1: Expansion Plans - The expansion of Symvess is driven by requests from surgeons and hospitals in Israel, with plans to extend into Europe and the Middle East [1][2]. - The company anticipates that the FDA approval of Symvess will facilitate faster commercialization pathways in these new territories [2]. Group 2: Clinical Data and Product Features - Positive three-year results from the V005 Phase 2/3 study of Symvess in extremity vascular repair provide the first long-term data in traumatic arterial repair using a biologic conduit [2]. - Symvess is designed to be available off-the-shelf, which is crucial for saving surgical time in emergency situations, and has shown low infection rates and high limb salvage rates [2]. Group 3: Company Overview - Humacyte is focused on developing universally implantable bioengineered human tissues and has received FDA approval for its ATEV in December 2024 for vascular trauma [3]. - The company is also conducting late-stage clinical trials for other vascular applications and has received various designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) [3].

Core Insights - Humacyte, Inc. announced the publication of long-term data on Symvess, a bioengineered vessel, demonstrating high limb salvage rates and low infection rates in extremity arterial trauma patients over a follow-up period of up to 36 months [1][2][3] Group 1: Study Results - The study published in the Journal of Vascular Surgery Cases, Innovations and Techniques found that Symvess maintained structural integrity, exhibited a 92.9% infection-free rate from months 3 to 36, and had limb salvage rates of 87.3% at 12 months and 82.5% at 24 months [1][2] - No deaths, amputations, or mechanical failures were attributed to Symvess, and there was no evidence of spontaneous ruptures or structural failures during the follow-up period [2][3] Group 2: Clinical Significance - The results represent the first prospective long-term data in traumatic arterial repair using an off-the-shelf biologic conduit, providing a reliable alternative when autologous vein grafts are not feasible [3][4] - Symvess is designed to be immediately available off-the-shelf, which is critical in emergency situations where time is of the essence [4] Group 3: Company Overview - Humacyte is developing a biotechnology platform for universally implantable bioengineered human tissues and has received FDA approval for the acellular tissue engineered vessel (ATEV) in the vascular trauma indication [13] - The company is also advancing other vascular applications and has received multiple designations from the FDA, including Regenerative Medicine Advanced Therapy (RMAT) designation for its ATEVs [13]

Core Insights - Humacyte, Inc. has secured a credit facility with Avenue Venture Opportunities Fund II, L.P. for up to $77.5 million, aimed at retiring existing debt and providing future financing opportunities [1][2] Financing Details - The credit agreement has a four-year term, with an initial tranche of $40 million fully funded at closing, and two additional tranches totaling up to $37.5 million contingent on certain conditions [1] - Proceeds from the initial tranche are primarily allocated to retire Humacyte's existing debt facility [1] Company Growth Plans - Humacyte plans to expand the use of its product Symvess® in both U.S. and international markets in 2026 [2] - The company anticipates interim results from its V012 Phase 3 trial in dialysis and the initiation of the first human study of its coronary tissue engineered vessel (CTEV) for coronary bypass graft surgery [2] Product Development and Regulatory Status - Humacyte is developing bioengineered human tissues and has received FDA approval for its acellular tissue engineered vessel (ATEV) for vascular trauma in December 2024 [4] - The ATEV is currently in late-stage clinical trials for other vascular applications, including arteriovenous access for hemodialysis and peripheral artery disease [4] - Preclinical development is ongoing for coronary artery bypass grafts, pediatric heart surgery, and treatment of type 1 diabetes [4] Strategic Partnerships - Avenue Venture Opportunities Fund expresses excitement in partnering with Humacyte, highlighting the significant patient needs addressed by Symvess [2][3]

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is presented as a key player in the AI energy sector, owning critical energy infrastructure assets that are essential for supporting the anticipated surge in energy demand from AI data centers [3][7] - This company is characterized as a "toll booth" operator in the AI energy boom, benefiting from the increasing need for energy as AI technologies expand [4][5] Market Position - The company is noted for its unique position in the market, being debt-free and holding a significant cash reserve, which is approximately one-third of its market capitalization [8][10] - It also has a substantial equity stake in another AI-related company, providing investors with indirect exposure to multiple growth opportunities in the AI sector [9][10] Strategic Advantages - The company is involved in large-scale engineering, procurement, and construction (EPC) projects across various energy sectors, including nuclear energy, which is crucial for America's future power strategy [7][8] - The current political climate, particularly the push for onshoring and increased U.S. LNG exports, positions this company favorably to capitalize on these trends [6][14] Future Outlook - The influx of talent into the AI sector is expected to drive continuous innovation and advancements, reinforcing the importance of investing in AI-related companies [12] - The potential for significant returns is emphasized, with projections suggesting a possible 100% return within 12 to 24 months for investors who act promptly [15]

Core Insights - Humacyte, Inc. (HUMA) has an average brokerage recommendation (ABR) of 1.50, indicating a consensus between Strong Buy and Buy based on recommendations from eight brokerage firms [2] - Six out of the eight recommendations are Strong Buy, representing 75% of the total recommendations [2] Brokerage Recommendations - The ABR is calculated based on actual recommendations from brokerage firms, but it may not be a reliable sole indicator for investment decisions [5] - Studies indicate that brokerage recommendations often show limited success in guiding investors towards stocks with the best price increase potential [5][11] - Analysts from brokerage firms tend to exhibit a positive bias in their ratings due to vested interests, leading to a higher number of favorable ratings compared to negative ones [6][11] Zacks Rank vs. ABR - The Zacks Rank is a proprietary stock rating tool that classifies stocks into five groups based on earnings estimate revisions, which are correlated with near-term stock price movements [8][12] - Unlike the ABR, which is based solely on brokerage recommendations, the Zacks Rank is a quantitative model that reflects timely changes in earnings estimates [10][13] - The Zacks Rank for Humacyte, Inc. is currently 2 (Buy), indicating positive sentiment based on recent earnings estimate revisions [15] Earnings Estimates - The Zacks Consensus Estimate for Humacyte, Inc. has increased by 11.7% over the past month to -$0.25, reflecting growing optimism among analysts regarding the company's earnings prospects [14] - The recent change in consensus estimates, along with other factors, has contributed to the Zacks Rank 2 for Humacyte, suggesting potential for stock appreciation [15]

Core Insights - Humacyte, Inc. presented significant findings on its acellular tissue engineered vessel (ATEV™) at the VEITHsymposium, highlighting its potential in vascular applications and regenerative medicine [1][2][3] Company Overview - Humacyte is a biotechnology platform company focused on developing universally implantable, bioengineered human tissues at commercial scale [1][8] - The company received FDA approval for its ATEV in December 2024 for vascular trauma indications and is conducting late-stage clinical trials for other vascular applications [8] ATEV Performance and Clinical Outcomes - ATEV demonstrated the ability to remodel into living vascular tissue, showing progressive recellularization with host cells, which is crucial for its function as a vascular graft [2][3] - In a study involving dialysis patients with Steal syndrome, ATEV showed durable patency and safety, with no graft-related infections or ruptures observed over a follow-up period of up to 35.9 months [3][4] - ATEV was reported to have superior patency and duration of use over two years compared to autogenous fistula in female patients, a subgroup with historically poor outcomes [10] Additional Research Findings - Presentations at the symposium included positive outcomes for ATEV in treating torso arterial trauma and high rates of limb salvage in trauma patients treated under humanitarian programs in Ukraine [4][10] - The ATEV's performance in complex cases suggests it could serve as a biologic alternative when autologous vein is not available, moving towards regenerative solutions in vascular surgery [4][5] Future Directions - Humacyte is exploring additional applications for ATEV, including coronary artery bypass grafts and treatment for type 1 diabetes, indicating a broadening scope of its innovative tissue engineering technology [8]